诺沃·诺迪斯克(Novo Nordisk)的股本跌至五年最低点, 尽管其重量损失药效低于伊莱·莉莉(Eli Lilly), Novo Nordisk's stock dropped to a five-year low after its obesity drug underperformed Eli Lilly’s, despite strong financials.

诺沃·诺迪斯克(Novo Nordisk)的股位在周一急剧下降,创下五年最低点,因为CagriSema(CagriSema)的肥胖药在关键的第三阶段试验中未能与Eli Lilly的tirzepatide(tirzepatide)匹配,导致“持有”的降级,并引发了出售。 Novo Nordisk shares fell sharply on Monday, hitting a five-year low, after its obesity drug CagriSema failed to match Eli Lilly’s tirzepatide in a key Phase 3 trial, prompting a downgrade to “hold” and triggering a sell-off. 股票破损低于43.50美元,这一关键支助水平,表明投资者信心减弱。 The stock broke below $43.50, a critical support level, signaling weakened investor confidence. 尽管财政结果强劲,包括124.3亿美元的收入和33%的净利润,但这一挫折突出显示,在减重的毒品市场上竞争日益激烈。 Despite strong financial results, including $12.43 billion in revenue and a 33% net margin, the setback highlights growing competition in the weight-loss drug market.